Skip to main content
. 2013 Jan 23;121(14):2715–2724. doi: 10.1182/blood-2012-10-461848

Figure 5.

Figure 5

Prognostic impact of concurrent EBV infection in CD30+ DLBCL. (A) OS of all CD30+EBER+ vs all CD30+EBER DLBCL patients. Age range, 52 to 91 for EBV+ group; 16 to 84 for EBV group. (B) OS of CD30+EBER+ vs CD30+EBER DLBCL patients in >60-year-old age group. Median age, 73 for EBV+ group; 70 for EBV group. (C) OS of CD30+EBV+ DLBCL patients in >50-year-old age group vs CD30+EBV DLBCL in >60-year-old age group. Median age, 70 for both groups.